Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
NCT ID: NCT01053936
Last Updated: 2025-05-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
129 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-01-31
Study Completion Date
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
NCT00811889
Chronic Kidney Disease
Type 2 Diabetes
Diabetic Nephropathy
COMPLETED
PHASE2
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01500798
Chronic Kidney Disease
Type 2 Diabetes
TERMINATED
PHASE1
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01549769
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
TERMINATED
PHASE1
Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy
NCT00664027
Diabetic Nephropathy
COMPLETED
PHASE2
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01351675
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bardoxolone methyl (RTA 402) is an Antioxidant Inflammation Modulator (AIM) that is undergoing clinical testing in chronic kidney disease (CKD). Bardoxolone methyl and other AIMs inhibit immune-mediated inflammation by restoring redox homeostasis in inflamed tissues through the induction of the cytoprotective transcription factor Nrf2. In the diabetic population, adipocytes produce cytokines and mobilize free fatty acids which induce insulin resistance. Resultant hyperglycemia and increased cytokine production induces reactive oxygen and nitrogen species which in turn induce vascular inflammation and endothelial dysfunction. These stimuli cause further activation of NF-kB, promoting inflammation, mesangial cell contraction, mesangial expansion and endothelial dysfunction, the end result of which is decreased renal function. By inducing Nrf2 and suppressing redox-driven inflammation, we hypothesize that inflammation and resultant adverse renal functional changes in patients with chronic kidney disease resulting from diabetes can be suppressed.
In a Phase IIa open label study of patients with CKD and type 2 diabetes, treatment with bardoxolone methyl for 28 days resulted in significant improvements in renal function, including increases in eGFR, and decreases in serum creatinine, cystatin C, BUN, phosphorus, uric acid, creatinine clearance, and angiotensin II; improvements in glycemic control as assessed by hemoglobin A1c; and improvements in markers of endothelial dysfunction and systemic inflammation, such as circulating endothelial cells and adiponectin. These data are consistent with the hypothesis that bardoxolone methyl improves renal function through suppression of renovascular oxidative stress and inflammation.
A new formulation of bardoxolone methyl has been developed, which is the same chemical entity but manufactured to contain an amorphous dispersion rather than a crystalline solid state. The new amorphous dispersion formulation of bardoxolone methyl has been shown to be more orally bioavailable in non-human primates. The purpose of this study is to determine the appropriate dose of the new bardoxolone methyl formulation to use in future clinical studies by determining the dose response relationship on eGFR.
In a Phase IIa open label study of patients with CKD and type 2 diabetes, treatment with bardoxolone methyl for 28 days resulted in significant improvements in renal function, including increases in eGFR, and decreases in serum creatinine, cystatin C, BUN, phosphorus, uric acid, creatinine clearance, and angiotensin II; improvements in glycemic control as assessed by hemoglobin A1c; and improvements in markers of endothelial dysfunction and systemic inflammation, such as circulating endothelial cells and adiponectin. These data are consistent with the hypothesis that bardoxolone methyl improves renal function through suppression of renovascular oxidative stress and inflammation.
A new formulation of bardoxolone methyl has been developed, which is the same chemical entity but manufactured to contain an amorphous dispersion rather than a crystalline solid state. The new amorphous dispersion formulation of bardoxolone methyl has been shown to be more orally bioavailable in non-human primates. The purpose of this study is to determine the appropriate dose of the new bardoxolone methyl formulation to use in future clinical studies by determining the dose response relationship on eGFR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bardoxolone methyl: 5 mg
Group Type
EXPERIMENTAL
Bardoxolone methyl (amorphous dispersion)
Intervention Type
DRUG
Oral, once daily
Bardoxolone methyl: 10 mg
Group Type
EXPERIMENTAL
Bardoxolone methyl (amorphous dispersion)
Intervention Type
DRUG
Oral, once daily
Bardoxolone methyl: 15 mg
Group Type
EXPERIMENTAL
Bardoxolone methyl (amorphous dispersion)
Intervention Type
DRUG
Oral, once daily
Bardoxolone methyl: 30 mg
Group Type
EXPERIMENTAL
Bardoxolone methyl (amorphous dispersion)
Intervention Type
DRUG
Oral, once daily
Bardoxolone methyl: 2.5 mg
Group Type
EXPERIMENTAL
Bardoxolone methyl (amorphous dispersion)
Intervention Type
DRUG
Oral, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bardoxolone methyl (amorphous dispersion)
Oral, once daily
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients must have a history of type 2 diabetes; diagnosis of type 2 diabetes should have been made at \>30 years of age (if diabetes developed at a younger age, C-peptide level may be obtained to confirm diagnosis);
2. Patients must be at least 18 years of age;
3. The average of 2 eGFR values collected during screening must be within 15 - 45 mL /min/1.73m2 inclusive.
4. Patients must be receiving an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) for at least 8 weeks prior to screening, where the dose of the ACE inhibitor or the ARB is considered appropriate for that patient, and the patient has been stable and maintained on that dose for at least 8 weeks prior to randomization (Day 1). No change in ACE or ARB therapy should be anticipated or planned for the period of the study.
5. Male and female patients must agree to use effective contraception during the entire study period and for at least 2 months after the last dose of study drug, unless documentation of infertility exists
6. Women of child-bearing potential must have a negative serum pregnancy test result at screening and a confirmed negative urine pregnancy test result prior to administration of the first dose of study medication;
7. Patient is willing and able to cooperate with all aspects of the protocol;
8. Patient is willing and able to give written informed consent for study participation
2. Patients must be at least 18 years of age;
3. The average of 2 eGFR values collected during screening must be within 15 - 45 mL /min/1.73m2 inclusive.
4. Patients must be receiving an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) for at least 8 weeks prior to screening, where the dose of the ACE inhibitor or the ARB is considered appropriate for that patient, and the patient has been stable and maintained on that dose for at least 8 weeks prior to randomization (Day 1). No change in ACE or ARB therapy should be anticipated or planned for the period of the study.
5. Male and female patients must agree to use effective contraception during the entire study period and for at least 2 months after the last dose of study drug, unless documentation of infertility exists
6. Women of child-bearing potential must have a negative serum pregnancy test result at screening and a confirmed negative urine pregnancy test result prior to administration of the first dose of study medication;
7. Patient is willing and able to cooperate with all aspects of the protocol;
8. Patient is willing and able to give written informed consent for study participation
Exclusion Criteria
1. Any patient with Type 1 (insulin-dependent; juvenile onset) diabetes; or any history of diabetic ketoacidosis;
2. Any patient with known non-diabetic renal disease, family history of a hereditary form of kidney disease, or patients with a history of a renal transplant.
3. Any patient with clinical or renal biopsy evidence of any non-diabetic renal disease other than nephro-sclerosis;
4. Any patient with blood pressure (BP) that is unable to be controlled to a systolic pressure (SeSBP) \<160 mmHg and a diastolic pressure (SeDBP) of \<90 mmHg. BP will be determined by the average of 3 readings, taken after being seated for at least 5-minutes. BP must be within this range taken at 2 separate time-points at least 4 days apart during the screening period;
5. Any patient with Hemoglobin A1c level \>10% collected at screening;
6. Any patient with cardiovascular disease as follows:
1. Unstable angina pectoris within 3 months before study randomization;
2. Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 3 months before study randomization;
3. Transient ischemic attack within 3 months before study randomization;
4. Cerebrovascular accident within 3 months before study randomization;
5. Obstructive valvular heart disease or hypertrophic cardiomyopathy;
6. 2nd degree or 3rd degree atrioventricular block not successfully treated with a pacemaker;
7. Current diagnosis of Class III or IV congestive heart failure ;
7. Any patient with QTc Fredericia interval \> 450 milliseconds as determined by the average of values reported by a central reader from 3 ECGs taken at the Screening Visit.
8. Any patient with need for chronic (\>2 weeks) immunosuppressive therapy, including corticosteroids (excluding intra-articular injections inhaled or nasal steroids) within 3 months prior to randomization;
9. Any patient who requires more than occasional (once or twice weekly) use of non-steroidal anti-inflammatory agents (NSAIDS);
10. Any patient who requires a change or dose adjustment in any of the following medications: ACE inhibitors and ARBs within 8 weeks; other anti-hypertensive, and other anti-diabetic medications within 6 weeks prior to study randomization;
11. Any patient who is unable or unwilling to discontinue the following medications throughout the study period: Niacin® (nicotinic acid), Niaspan® (nicotinic acid), Niacor® (nicotinic acid), Nicolar® (nicotinic acid),Nicobid® (nicotinic acid), Nydrazid® (isoniazid), Dantrium® (dantrolene), Normodyne® (labetalol), Trandate® (labetalol), Cylert® (pemoline), Tradon® (pemoline), PemADD® (pemoline), Felbatol® (felbamate), Zyflo® (zileuton),Tasmar® (tolcapone), or Tricor® (fenofibrate), Antaram® (fenofibrate), Triglide® (fenofibrate), Lofibra® (fenofibrate), Lipidil Micro® (fenofibrate), Lipidil Supra® (fenofibrate); including fenofibrate derivatives e.g. Lopid® (gemfibrozil) and Atromid-S® (clofibrate) . Patient must discontinue the aforementioned medications for a minimum of two weeks prior to randomization. Patients may continue use of multi-vitamins (e.g., Centrum) ®, which have a maximum total daily consumption of \<= 50 mg of nicotinic acid (Niacin®);
12. Any patient with evidence of hepatic or biliary dysfunction including levels of total bilirubin \>1.0 mg/dL (\>17 micromole/L), aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> upper limit of normal (ULN), or alkaline phosphatase \>2.0 times the ULN on ANY screening laboratory test result;
13. If a patient provides a history of hepatitis B or C but has normal liver enzyme levels, the investigator should perform a serologic hepatitis screen and call the Medical Monitor to discuss patient eligibility. Patients with a history of hepatitis A that is resolved and who do not demonstrate any liver enzyme level elevation are eligible for protocol randomization;
14. Any female patient who is pregnant, nursing or planning a pregnancy;
15. Any patient with known hypersensitivity to any component of the study drug;
16. Any patient who has undergone diagnostic or intervention procedure requiring a contrast agent within the last 30 days prior to study randomization;
17. Patient with a current history of drug or alcohol abuse as per the Investigator's assessment;
18. Any patient with a history of neoplastic disease (except basal or squamous cell carcinoma of the skin) within 5 years prior to study randomization;
19. Any patient who has had dialysis within 3 months before randomization and/or have not maintained a stable level of kidney function within 3 months of randomization per Investigator assessment;
20. Any patient who has any concurrent clinical conditions that in the judgment of the investigator could either potentially pose a health risk to the patient while involved in the study or could potentially influence the study outcome;
21. Any patient who has participated in another clinical study involving investigational or marketed products within 30 days prior to randomization or would concomitantly participate in such a study, or any patient who has received bardoxolone methyl in any form;
22. Any patient who is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function.
2. Any patient with known non-diabetic renal disease, family history of a hereditary form of kidney disease, or patients with a history of a renal transplant.
3. Any patient with clinical or renal biopsy evidence of any non-diabetic renal disease other than nephro-sclerosis;
4. Any patient with blood pressure (BP) that is unable to be controlled to a systolic pressure (SeSBP) \<160 mmHg and a diastolic pressure (SeDBP) of \<90 mmHg. BP will be determined by the average of 3 readings, taken after being seated for at least 5-minutes. BP must be within this range taken at 2 separate time-points at least 4 days apart during the screening period;
5. Any patient with Hemoglobin A1c level \>10% collected at screening;
6. Any patient with cardiovascular disease as follows:
1. Unstable angina pectoris within 3 months before study randomization;
2. Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 3 months before study randomization;
3. Transient ischemic attack within 3 months before study randomization;
4. Cerebrovascular accident within 3 months before study randomization;
5. Obstructive valvular heart disease or hypertrophic cardiomyopathy;
6. 2nd degree or 3rd degree atrioventricular block not successfully treated with a pacemaker;
7. Current diagnosis of Class III or IV congestive heart failure ;
7. Any patient with QTc Fredericia interval \> 450 milliseconds as determined by the average of values reported by a central reader from 3 ECGs taken at the Screening Visit.
8. Any patient with need for chronic (\>2 weeks) immunosuppressive therapy, including corticosteroids (excluding intra-articular injections inhaled or nasal steroids) within 3 months prior to randomization;
9. Any patient who requires more than occasional (once or twice weekly) use of non-steroidal anti-inflammatory agents (NSAIDS);
10. Any patient who requires a change or dose adjustment in any of the following medications: ACE inhibitors and ARBs within 8 weeks; other anti-hypertensive, and other anti-diabetic medications within 6 weeks prior to study randomization;
11. Any patient who is unable or unwilling to discontinue the following medications throughout the study period: Niacin® (nicotinic acid), Niaspan® (nicotinic acid), Niacor® (nicotinic acid), Nicolar® (nicotinic acid),Nicobid® (nicotinic acid), Nydrazid® (isoniazid), Dantrium® (dantrolene), Normodyne® (labetalol), Trandate® (labetalol), Cylert® (pemoline), Tradon® (pemoline), PemADD® (pemoline), Felbatol® (felbamate), Zyflo® (zileuton),Tasmar® (tolcapone), or Tricor® (fenofibrate), Antaram® (fenofibrate), Triglide® (fenofibrate), Lofibra® (fenofibrate), Lipidil Micro® (fenofibrate), Lipidil Supra® (fenofibrate); including fenofibrate derivatives e.g. Lopid® (gemfibrozil) and Atromid-S® (clofibrate) . Patient must discontinue the aforementioned medications for a minimum of two weeks prior to randomization. Patients may continue use of multi-vitamins (e.g., Centrum) ®, which have a maximum total daily consumption of \<= 50 mg of nicotinic acid (Niacin®);
12. Any patient with evidence of hepatic or biliary dysfunction including levels of total bilirubin \>1.0 mg/dL (\>17 micromole/L), aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> upper limit of normal (ULN), or alkaline phosphatase \>2.0 times the ULN on ANY screening laboratory test result;
13. If a patient provides a history of hepatitis B or C but has normal liver enzyme levels, the investigator should perform a serologic hepatitis screen and call the Medical Monitor to discuss patient eligibility. Patients with a history of hepatitis A that is resolved and who do not demonstrate any liver enzyme level elevation are eligible for protocol randomization;
14. Any female patient who is pregnant, nursing or planning a pregnancy;
15. Any patient with known hypersensitivity to any component of the study drug;
16. Any patient who has undergone diagnostic or intervention procedure requiring a contrast agent within the last 30 days prior to study randomization;
17. Patient with a current history of drug or alcohol abuse as per the Investigator's assessment;
18. Any patient with a history of neoplastic disease (except basal or squamous cell carcinoma of the skin) within 5 years prior to study randomization;
19. Any patient who has had dialysis within 3 months before randomization and/or have not maintained a stable level of kidney function within 3 months of randomization per Investigator assessment;
20. Any patient who has any concurrent clinical conditions that in the judgment of the investigator could either potentially pose a health risk to the patient while involved in the study or could potentially influence the study outcome;
21. Any patient who has participated in another clinical study involving investigational or marketed products within 30 days prior to randomization or would concomitantly participate in such a study, or any patient who has received bardoxolone methyl in any form;
22. Any patient who is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montgomery, Alabama, United States
Site Status
Phoenix, Arizona, United States
Site Status
Tempe, Arizona, United States
Site Status
La Mesa, California, United States
Site Status
Riverside, California, United States
Site Status
San Dimas, California, United States
Site Status
Washington D.C., District of Columbia, United States
Site Status
Brandon, Florida, United States
Site Status
Port Charlotte, Florida, United States
Site Status
West Palm Beach, Florida, United States
Site Status
Augusta, Georgia, United States
Site Status
Canton, Georgia, United States
Site Status
Chicago, Illinois, United States
Site Status
Peoria, Illinois, United States
Site Status
Brooklyn Center, Minnesota, United States
Site Status
Morehead City, North Carolina, United States
Site Status
Winston-Salem, North Carolina, United States
Site Status
Pittsburgh, Pennsylvania, United States
Site Status
Providence, Rhode Island, United States
Site Status
Chattanooga, Tennessee, United States
Site Status
Corpus Christi, Texas, United States
Site Status
Dallas, Texas, United States
Site Status
Greenville, Texas, United States
Site Status
Houston, Texas, United States
Site Status
San Antonio, Texas, United States
Site Status
Federal Way, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RTA 402-C-0902
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01551446
WITHDRAWN
PHASE1
The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
NCT02316821
COMPLETED
PHASE2
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
NCT03550378
COMPLETED
PHASE2
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
NCT01555008
COMPLETED
PHASE1
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
NCT01574365
TERMINATED
PHASE2
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
NCT01948986
COMPLETED
PHASE1
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532
NCT01369602
COMPLETED
PHASE1
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
NCT01572610
TERMINATED
PHASE2
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
NCT05510245
TERMINATED
PHASE1
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
NCT00663260
COMPLETED
PHASE2/PHASE3
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05897372
TERMINATED
PHASE2
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
NCT01407276
COMPLETED
PHASE1
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
NCT05374343
UNKNOWN
PHASE1
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495
COMPLETED
PHASE2
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
NCT01847092
COMPLETED
PHASE2
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
NCT01487109
COMPLETED
PHASE2
A Phase 2b Diabetic Kidney Disease Study
NCT04170543
COMPLETED
PHASE2
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
NCT00368368
COMPLETED
PHASE1
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
NCT04990427
COMPLETED
PHASE1
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
NCT04616027
COMPLETED
PHASE1
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
NCT01986855
COMPLETED
PHASE3
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
NCT04515849
COMPLETED
PHASE2
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
NCT02312050
UNKNOWN
PHASE2
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers
NCT07304726
COMPLETED
PHASE1
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05536804
ACTIVE_NOT_RECRUITING
PHASE2